# Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma

> **NCT05221398** · — · COMPLETED · sponsor: **Guangxi Medical University** · enrollment: 517 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Immune Checkpoint Inhibitors Based Adjuvant therapy
- **OTHER:** Active surveillance

## Key facts

- **NCT ID:** NCT05221398
- **Lead sponsor:** Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-03
- **Primary completion:** 2023-01-18
- **Final completion:** 2023-03-17
- **Target enrollment:** 517 (ACTUAL)
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05221398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05221398, "Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05221398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*